Trust Signals
BPC-157 has the broadest mechanistic plausibility for endurance recovery and vascular support, but human RCT data is absent. For direct VO2 or mitochondrial effects, no peptide currently has high-quality human trial evidence comparable to established non-peptide interventions like beta-alanine or creatine.
Does BPC-157 improve cardio endurance?
Animal and in-vitro studies show BPC-157 promotes angiogenesis via VEGFR2 upregulation and reduces inflammation, which could support endurance capacity indirectly. No published human RCT has tested VO2 max or time-to-exhaustion outcomes with BPC-157.
What does TB-500 do for endurance athletes?
TB-500 is a synthetic fragment of Thymosin Beta-4 corresponding to a region of the protein associated with actin binding. Animal and in-vitro studies show it may reduce recovery time after cardiac or musculoskeletal stress. Its main proposed benefit for endurance is faster tissue repair between sessions, not direct aerobic output. Human evidence is very limited, and it is explicitly prohibited by WADA.
Is AOD-9604 useful for cardio performance?
AOD-9604 is a C-terminal fragment of growth hormone studied primarily for fat metabolism. Some researchers speculate fat oxidation improvements could benefit endurance, but no human trial has measured aerobic performance outcomes specifically.
Can oral peptides work for endurance benefits?
Most endurance-relevant peptides are too large or too charge-sensitive to survive gastric proteolysis intact. Oral bioavailability for peptides like BPC-157 is debated; animal gavage studies exist but do not establish systemic plasma concentrations equivalent to injectable doses in humans.
Are endurance peptides legal in competitive sport?
WADA prohibits several peptide hormones and growth-factor mimetics under S2. TB-500 (Thymosin Beta-4) is specifically listed. BPC-157 is not currently named but falls under the catch-all S0 clause for non-approved substances. Athletes should verify status with their governing body before use.
What is the correct dose of BPC-157 for endurance support?
Animal studies have used roughly 1 to 10 mcg/kg body weight injected subcutaneously or intraperitoneally. No validated human dose exists. Extrapolating from rodent studies to human dosing involves considerable uncertainty and is not endorsed by any regulatory authority.
How do I read a COA for a research peptide?
Look for HPLC purity above 98%, mass spectrometry confirmation of molecular weight, and endotoxin testing by the LAL method (below 1 EU/mg is a common benchmark). A COA without MS confirmation or endotoxin data is incomplete and represents a sourcing red flag.
Which peptide has the strongest evidence for heart-related endurance?
In animal cardiac injury models, BPC-157 has shown protection of cardiac tissue and promotion of collateral vessel formation. Thymosin Alpha-1 has human data but in immune contexts, not endurance. No peptide has human RCT evidence for cardiac endurance output specifically.
How does BPC-157 compare to non-peptide endurance aids?
Compared to beta-alanine (human RCT evidence for buffering capacity, roughly 2 to 3% improvement in high-intensity work per the Hobson et al. 2012 meta-analysis) or beetroot juice nitrates (human RCT evidence for VO2 economy), BPC-157 has no comparable human efficacy data and loses on evidence quality.
What are the main safety concerns with endurance peptides?
Risks include injection-site reactions, unknown long-term effects, contamination from under-regulated research sources, and potential tumor-promoting effects of growth-promoting peptides in susceptible individuals. BPC-157 animal safety data is generally favorable but human safety trials are absent.
Sources
- Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Current Pharmaceutical Design, 2011. PMID: 21473737.
- Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." Journal of Applied Physiology, 2011. PMID: 21512148.
- Hsieh MJ, et al. "Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation." Journal of Molecular Medicine, 2017. PMID: 28236009.
- Smart N, et al. "Thymosin beta4 and progenitor cells." Annals of the New York Academy of Sciences, 2010. PMID: 20624213.
- Lee C, et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism, 2015. PMID: 25738459.
- Reynolds JC, et al. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nature Communications, 2021. PMID: 33947860.
- Hobson RM, et al. "Effects of beta-alanine supplementation on exercise performance: a meta-analysis." Amino Acids, 2012. PMID: 22270875.
- Hoon MW, et al. "The effect of nitrate supplementation on exercise performance in healthy individuals: a systematic review." International Journal of Sport Nutrition and Exercise Metabolism, 2013. PMID: 23580439.
- World Anti-Doping Agency. 2024 Prohibited List. wada-ama.org. Accessed May 2026.
- FDA. BPC-157 Compounding Notice. FDA.gov, 2022. Available at: fda.gov.
- Walker RF. "Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?" Clinical Interventions in Aging, 2006. PMID: 18046877.
- Sigalos JT, Pastuszak AW. "The Safety and Efficacy of Growth Hormone Secretagogues." Sexual Medicine Reviews, 2018. PMID: 28859955.
Related peptide guides
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →